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Sex differences in discharge therapy in young patients with acute 
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Introduction: Acute coronary syndrome (ACS), including ST-segment elevation myocardial infarction 
(STEMI), non-ST-elevation myocardial infarction (NSTEMI) and unstable angina pectoris (UA), has 
been less researched in the subpopulation of young patients. Sex differences in discharge therapy 
after ACS have been described in older patients as favouring the male sex1, and we decided to test this 
hypothesis in young patients. The term “young” (with regard to ACS) is not uniquely defined, but ac-
cording to multiple sources, the proposed cut-off age is 45 years2.
Patients and Methods: A total of 361 young patients (with an age cut-off of 45 years for men and 55 
years for women) with ACS and percutaneous coronary intervention (PCI) performed at the University 
Hospital Centre Zagreb (UHCZG) between Jan 1st 2012 and Jan 1st 2020 were enrolled. The patients were 
divided into the UHCZG group (241 patients discharged home after ACS) and the PCI network group (120 
patients transferred to another medical facility after ACS). We explored statistically relevant associa-
tions between sex and discharge therapy using the Pearson chi-square test in the UHCZG group, due 
to the completeness of this dataset.
Results: The mean patient age in the UH-
CZG group was 44±7 years, and 148 (61.4%) 
were men. 139 (57.9%) patients had STEMI, 
72 (30.0%) NSTEMI, and 29 (12.1%) had UA 
(Table 1, Figure 1). Female patients had 
a higher prevalence of hypothyroidism, 
lower diastolic blood pressure at admission 
and higher LDL values (Table 1). A signifi-
cantly higher proportion of male patients 
were prescribed with angiotensin-convert-
ing enzyme inhibitors (ACEi) (82.4% versus 
65.6%, p=0.003). There were no sex differ-
ences in the prescription of other cardio-
vascular drugs (Table 2).
Conclusion: In a group of young patients 
with ACS, we found a statistically signifi-
cant difference between male and female 
patients regarding the prescription of ACEi, 
despite a lack of significant difference in 
systolic blood pressure. Results similar to 
ours, regarding sex differences in optimal 
medical therapy, have been described in 
the literature, including young ACS pa-
tients3.These results raise concerns regard-
ing potentially negative consequences on 
the health of young women treated for ACS.
 Figure 1. Pie chart showing the distribution of types 
of acute coronary syndrome in the university Hospital 
Centre Zagreb group. 
STeMi – ST-segment elevation myocardial infarction; 
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TABLE 1. Baseline patient characteristics by sex in the University Hospital Centre Zagreb group.
Characteristic UHCZG group - women (n = 93) UHCZG group - men (n = 148) p-value
Age, years 50 ± 5 41 ± 4 < 0.001
BMI, kg/m2 27.9 ± 6.6 29.9 ± 5.4 0.018
ACS type
STEMI 50 (53.8) 89 (60.5) 0.298*
NSTEMI 29 (31.2) 43 (29.3) 0.749*
Unstable angina 14 (15.1) 15 (10.2) 0.263*
Arterial hypertension 53 (57.0) 78 (52.7) 0.516
Diabetes mellitus 16 (17.2) 14 (9.5) 0.077
Hypothyroidism 7 (7.6) 2 (1.4) 0.013
Dyslipidemia 47 (50.5) 77 (52.0) 0.818
Family history of CVD
CVD at younger age 10 (18.2) 15 (15.6) 0.682**
CVD at older age 8 (14.5) 10 (10.4) 0.453**
CVD at unknown age 11 (20.0) 11 (11.5) 0.153**
Previous myocardial infarction 12 (12.9) 16 (10.9) 0.638
Previous TIA or CVA 1 (1.1) 2 (1.4) 0.849
Previous angina pectoris 32 (34.8) 38 (25.7) 0.131
Smoking status
Non-smoker 20 (22.2) 20 (14.3) 0.121*
Former smoker 6 (6.7) 11 (7.9) 0.734*
Current smoker 64 (71.1) 109 (77.9) 0.246*
Number of significant coronary stenoses
0 0 (0.0) 5 (3.4) 0.073**
1 58 (63.0) 95 (65.1) 0.749**
2 17 (18.5) 36 (24.7) 0.263**
3 17 (18.5) 10 (6.8) 0.006**
Culprit vessel
LAD 36 (39.1) 64 (44.1) 0.447*
LCX 17 (18.5) 28 (19.3) 0.873*
RCA 39 (42.4) 48 (33.1) 0.147*
Dominant coronary artery
Right 65 (83.3) 102 (78.5) 0.390*
Left 7 (9.0) 20 (15.4) 0.184*
Co-dominance 6 (7.7) 8 (6.2) 0.667*
Systolic BP at admission, mmHg 138 ± 29 142 ± 25 0.265
Diastolic BP at admission, mmHg 85 ± 16 90 ± 17 0.011
Heart rate at admission, beats/min 77 ± 18 80 ± 17 0.369
Total cholesterol, mmol/L 5.15 ± 1.34 5.07 ± 1.35 0.706
Triglycerides, mmol/L 1.77 ± 0.88 2.04 ± 1.33 0.094
HDL, mmol/L 1.17 ± 0.39 0.96 ± 0.27 < 0.001
LDL, mmol/L 3.19 ± 1.26 3.23 ± 1.19 0.809
If not otherwise marked, significance determined at p-value of 0.05. *significance of p-value = 0.008 (due to Bonferroni correction) ** significance of p-value = 0.006 
(due to Bonferroni correction). 
UHCZG – University Hospital Centre Zagreb; BMI – body mass index; ACS – acute coronary syndrome; STEMI – ST-segment elevation myocardial infarction; NSTEMI 
– non-ST-elevation myocardial infarction; CVD – cardiovascular disease; TIA – transient ischemic attack; CVA – cerebral vascular accident; LAD – left anterior 
descending artery; LCX – left circumflex artery; RCA – right coronary artery; BP – blood pressure; HDL – high-density lipoprotein; LDL – low-density lipoprotein.
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TABLE 2. Sex differences in discharge therapy in the University Hospital Centre Zagreb group.
Drug class UHCZG group - women (n = 93) UHCZG group - men (n = 148) p-value
Acetylsalicylic acid 88 (94.6) 144 (97.3) 0.287
Anti-platelet therapy
Ticagrelor 40 (43.0) 63 (42.6) 0.944*
Clopidogrel 51 (54.8) 79 (53.4) 0.826*
Beta-blocker 81 (87.1) 129 (87.2) 0.988
RAAS inhibitor
ACE inhibitor 61 (65.6) 122 (82.4) 0.003*
ARB 8 (8.6) 6 (4.1) 0.142*
MRA 10 (10.8) 24 (16.2) 0.236
Nitrate 29 (31.2) 37 (25.0) 0.295
Statin
Atorvastatin 81 (87.1) 135 (91.2) 0.308**
Rosuvastatin 7 (7.5) 11 (7.4) 0.976**
Simvastatin 0 (0) 1 (0.7) 0.430**
Antiischemic drug 15 (16.1) 22 (14.9) 0.791
Calcium channel blocker 24 (25.8) 24 (16.2) 0.070
Antiarrhythmic drug 4 (4.3) 9 (6.1) 0.552
Diuretic 20 (21.5) 23 (15.5) 0.239
Fibrate 3 (3.2) 6 (4.1) 0.741
Omega-3-fatty acid 13 (14.0) 29 (19.6) 0.263
If not otherwise marked, significance determined at p-value of 0.05. * - significance of p-value = 0,008 (due to Bonferroni correction) ** - significance of p-value = 0,006 
(due to Bonferroni correction). 
UHCZG – University Hospital Centre Zagreb; RAAS – renin-angiotensin-aldosterone system; ACE – angiotensin-converting enzyme; ARB – angiotensin II receptor 
blocker; MRA – mineralocorticoid receptor antagonist.
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